Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This study will determine the tissue penetration of tedizolid (Sivextro, Merck & Co.), a
novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in
diabetic patients with lower limb wound infections. Penetration will be compared with a group
of healthy volunteer control participants.